Company Strategy

Dimerix Investment

Dimerix is adopting a diversified investment approach, targeting a
range of speciality innovative new chemical entities (NCE’s) along with re-purposed candidates providing a balanced approach and a reduced risk when compared with development of NCE’s alone.

Currently the Dimerix business has two distinct opportunities:

DMX-200 for FSGS, which is currently in a Phase 3 clinical trial and has been granted Orphan Drug Designation by the FDA & EMEA
DMX-700 for chronic obstructive pulmonary disease (COPD), which is in pre-clinical development

The Dimerix approach to business strategy

  • Developing and applying Dimerix proprietary Receptor-HIT technology across a broad range of therapeutic classes, using existing drugs and New Chemical Entities (NCE’s).
  • Evaluating other opportunities through mergers, licencing and acquisitions that build the Dimerix pipeline.
  • Developing strong proprietary positions through patents to maintain and extend competitive advantages for existing and new drugs.
  • Creating a diversified portfolio of products to generate future income streams.
  • Build and develop a solid product pipeline that has an attractive projected internal rate of return.
  • Establish a culture of shared leadership and accountability.
  • Build strong strategic partnerships which will enhance expertise and / or mitigate the capital obligations and commercial risk.

We use our innovative receptor technology in order to uncover pharmaceutical products that will improve patient’s lives.